Yuval Cohen
Known title: Chief Executive OfficerCIK: 0001626003
Yuval Cohen's purchase track record
How the stock did after each of Yuval Cohen's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since March 9, 2022
Stock higher 6 months later
0%
3 months: 0%
Median 6-month return
-45.5%
3 months: -20.2%
Beat the S&P 500
0%
median -38.5% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/10/2022 | CRBP | $1K | -51.0% | -32.6% | -2.2% |
| 5/16/2022 | CRBP | $3K | -13.8% | -53.4% | -1.3% |
| 3/9/2022 | CRBP | $3K | -20.2% | -45.5% | -7.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CRBP | ▼ Sell | Open Market | 17,000 | $171K | 8/7/2026 | View on chart |
| CRBP | ▼ Sell | Open Market | 13,871 | $108K | 2/13/2026 | View on chart |
| CRBP | ▲ Buy | Grant | 50,000 | $0 | 1/14/2026 | View on chart |
| CRBP | ▲ Buy | Option Exercise | 8,973 | $38K | 10/27/2025 | View on chart |
| CRBP | ▼ Sell | Open Market | 8,973 | $154K | 10/27/2025 | View on chart |
| CRBP | ▲ Buy | Option Exercise | 18,660 | $79K | 10/24/2025 | View on chart |
| CRBP | ▼ Sell | Open Market | 18,660 | $317K | 10/24/2025 | View on chart |
| CRBP | ▼ Sell | Open Market | 7,134 | $62K | 2/14/2025 | View on chart |
| CRBP | ▲ Buy | Grant | 68,100 | $0 | 1/31/2025 | View on chart |
| CRBP | ▲ Buy | Option Exercise | 11,667 | $350K | 6/18/2024 | View on chart |
| CRBP | ▼ Sell | Open Market | 11,667 | $493K | 6/18/2024 | View on chart |
| CRBP | ▲ Buy | Option Exercise | 1,770 | $25K | 6/18/2024 | View on chart |
| CRBP | ▼ Sell | Open Market | 1,770 | $75K | 6/18/2024 | View on chart |
| CRBP | ▲ Buy | Option Exercise | 2,322 | $10K | 6/18/2024 | View on chart |
| CRBP | ▼ Sell | Open Market | 2,322 | $98K | 6/18/2024 | View on chart |
| CRBP | ▼ Sell | Open Market | 7,179 | $303K | 6/18/2024 | View on chart |
| CRBP | ▲ Buy | Option Exercise | 9,333 | $280K | 6/17/2024 | View on chart |
| CRBP | ▼ Sell | Open Market | 9,333 | $430K | 6/17/2024 | View on chart |
| CRBP | ▲ Buy | Option Exercise | 1,770 | $8K | 6/17/2024 | View on chart |
| CRBP | ▼ Sell | Open Market | 1,770 | $81K | 6/17/2024 | View on chart |
| CRBP | ▲ Buy | Option Exercise | 16,830 | $237K | 6/14/2024 | View on chart |
| CRBP | ▼ Sell | Open Market | 16,830 | $844K | 6/14/2024 | View on chart |
| CRBP | ▲ Buy | Option Exercise | 12,487 | $53K | 6/14/2024 | View on chart |
| CRBP | ▼ Sell | Open Market | 12,487 | $626K | 6/14/2024 | View on chart |
| CRBP | ▲ Buy | Grant | 73,947 | $0 | 2/12/2024 | View on chart |
| CRBP | ▲ Buy | Option Exercise | 7,179 | $36K | 1/26/2024 | View on chart |
| CRBP | ▲ Buy | Open Market | 3,800 | $1K | 8/10/2022 | View on chart |
| CRBP | ▲ Buy | Open Market | 10,500 | $3K | 5/16/2022 | View on chart |
| CRBP | ▲ Buy | Open Market | 8,600 | $3K | 3/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Corbus Doses First Patient in CRB-701 TEMPO-1 Study
Corbus Pharmaceuticals announced that the first patient has been dosed in the TEMPO-1 registrational study for CRB-701. This clinical trial focuses on patients with second-line or later oropharyngeal cancer. The update marks a significant step in the development timeline for the company's lead asset.
Corbus Doses First Patient in CRB-701 TEMPO-1 Study. Corbus Pharmaceuticals announced that the first patient has been dosed in the TEMPO-1 registrational study for CRB-701. This clinical trial focuses on patients with second-line or later oropharyngeal cancer. The update marks a significant step in the development timeline for the company's lead asset.